Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ampio Pharmaceuticals (NYSE:AMPEGet Rating) in a research report released on Monday. The brokerage issued a sell rating on the stock.

Ampio Pharmaceuticals Price Performance

Shares of AMPE opened at $0.09 on Monday. Ampio Pharmaceuticals has a twelve month low of $0.08 and a twelve month high of $1.83.

Ampio Pharmaceuticals Company Profile

(Get Rating)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19.

Recommended Stories

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.